BACKGROUND AND OBJECTIVE: In cystic fibrosis (CF) very few studies have assessed sputum 8-iso-PGF2alpha levels during pulmonary exacerbations as a direct measure of airway oxidative stress. The role of other lipid-derived inflammatory mediators, such as the cysteinyl leukotrienes (cys-LTs) and prostaglandin (PG)-E2, during exacerbations is also poorly defined and the effect of conventional antibiotic therapy on these components of the inflammatory process is unclear. METHODS: Sputum 8-iso-PGF2alpha, total cys-LT and PGE2 levels were measured in 17 CF patients experiencing a pulmonary exacerbation and repeated analysis were performed in 15 of these patients after antibiotic treatment. Eight stable CF and nine healthy subjects provided control data. RESULTS: Sputum 8-iso-PGF2alpha was significantly elevated in acute, but not stable CF patients versus healthy controls (P < 0.001). Similarly, sputum cys-LT and PGE2 levels were increased in acute compared with stable CF patients and healthy controls (P <or= 0.001). Although substantially lower than in acute patients, sputum cys-LT levels in stable patients were also significantly higher than in normal controls (P = 0.01). There were strong associations between cys-LT levels and sputum total cell counts, and blood neutrophils in acute patients (r2 = 0.53, P = 0.001 and r2 = 0.33, P < 0.05, respectively). Overall in the CF patients, FEV1% predicted was strongly and negatively correlated with sputum 8-iso-PGF2alpha (r2 = 0.34, P = 0.006), cys-LT (r2 = 0.40, P = 0.002) and PGE2 (r2 = 0.52, P < 0.001) levels. Antibiotic treatment reduced sputum total cell count (P = 0.03), but did not affect 8-iso-PGF2alpha, cys-LT or PGE2 levels. CONCLUSIONS: CF exacerbations are characterized by increased oxidative stress and sputum concentrations of bioactive lipid mediators. Treatment does not modulate these aspects of inflammation and more targeted therapy needs further study.
BACKGROUND AND OBJECTIVE: In cystic fibrosis (CF) very few studies have assessed sputum 8-iso-PGF2alpha levels during pulmonary exacerbations as a direct measure of airway oxidative stress. The role of other lipid-derived inflammatory mediators, such as the cysteinyl leukotrienes (cys-LTs) and prostaglandin (PG)-E2, during exacerbations is also poorly defined and the effect of conventional antibiotic therapy on these components of the inflammatory process is unclear. METHODS: Sputum 8-iso-PGF2alpha, total cys-LT and PGE2 levels were measured in 17 CF patients experiencing a pulmonary exacerbation and repeated analysis were performed in 15 of these patients after antibiotic treatment. Eight stable CF and nine healthy subjects provided control data. RESULTS: Sputum 8-iso-PGF2alpha was significantly elevated in acute, but not stable CF patients versus healthy controls (P < 0.001). Similarly, sputum cys-LT and PGE2 levels were increased in acute compared with stable CF patients and healthy controls (P <or= 0.001). Although substantially lower than in acute patients, sputum cys-LT levels in stable patients were also significantly higher than in normal controls (P = 0.01). There were strong associations between cys-LT levels and sputum total cell counts, and blood neutrophils in acute patients (r2 = 0.53, P = 0.001 and r2 = 0.33, P < 0.05, respectively). Overall in the CF patients, FEV1% predicted was strongly and negatively correlated with sputum 8-iso-PGF2alpha (r2 = 0.34, P = 0.006), cys-LT (r2 = 0.40, P = 0.002) and PGE2 (r2 = 0.52, P < 0.001) levels. Antibiotic treatment reduced sputum total cell count (P = 0.03), but did not affect 8-iso-PGF2alpha, cys-LT or PGE2 levels. CONCLUSIONS: CF exacerbations are characterized by increased oxidative stress and sputum concentrations of bioactive lipid mediators. Treatment does not modulate these aspects of inflammation and more targeted therapy needs further study.
Authors: C Staerck; P Vandeputte; A Gastebois; A Calenda; S Giraud; N Papon; J P Bouchara; M J J Fleury Journal: Mycopathologia Date: 2017-06-21 Impact factor: 2.574
Authors: Hamed Horati; Hettie M Janssens; Camilla Margaroli; Mieke Veltman; Marta Stolarczyk; Matthew B Kilgore; Jeffrey Chou; Limin Peng; Harm A M W Tiddens; Joshua D Chandler; Rabindra Tirouvanziam; Bob J Scholte Journal: J Cyst Fibros Date: 2020-02-10 Impact factor: 5.482
Authors: David P Nichols; Assem G Ziady; Samuel L Shank; Jean F Eastman; Pamela B Davis Journal: Am J Physiol Lung Cell Mol Physiol Date: 2009-08-21 Impact factor: 5.464
Authors: Delphine L Chen; Timothy J Bedient; James Kozlowski; Daniel B Rosenbluth; Warren Isakow; Thomas W Ferkol; Betsy Thomas; Mark A Mintun; Daniel P Schuster; Michael J Walter Journal: Am J Respir Crit Care Med Date: 2009-07-02 Impact factor: 21.405
Authors: Jun Yang; Jason P Eiserich; Carroll E Cross; Brian M Morrissey; Bruce D Hammock Journal: Free Radic Biol Med Date: 2012-05-08 Impact factor: 7.376
Authors: Shama Ahmad; David P Nichols; Matthew Strand; Raymond C Rancourt; Scott H Randell; Carl W White; Aftab Ahmad Journal: PLoS One Date: 2011-11-11 Impact factor: 3.240